{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"29.2","value":"14.6"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"26.8","value":"12.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"CrCl was calculated from blood samples using the Cockcroft-Gault formula. Relevant deterioration in renal function was defined as CrCl reduction of 30% from Baseline or an absolute value ≤30 mL/min at Week 92. The last available value on/before Week 92 was used in the calculation. The percentage of participants with deterioration in renal function at Week 92 was reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with multiple myeloma received ibandronate via 15-minute IV infusion as 6 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG000","title":"Ibandronate"},{"description":"Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.","id":"OG001","title":"Zoledronate"}],"paramType":"NUMBER","populationDescription":"ITT Population.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 92","title":"Percentage of Participants With Deterioration in Renal Function According to Reduction in CrCl From Baseline to Week 92","type":"PRIMARY","unitOfMeasure":"percentage of participants"}